AmacaThera与默克动物保健宣布在动物健康领域展开合作-动脉网

AmacaThera and Merck Animal Health Announce Collaboration in Animal Health

CISION 等信源发布 2025-05-01 19:59



可切换为仅中文







TORONTO

多伦多

，

May 1, 2025

2025年5月1日

/PRNewswire/ - AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting formulations, for use in animal health.

/PRNewswire/ - AmacaThera，一家专注于药物递送的临床阶段生物技术公司，宣布已与默克动物健康部门签署了一份具有约束力的评估与选择协议，以开发用于动物健康的长效制剂。

Built upon AmacaThera's unique hydrogel platform technology, AmacaGel

基于AmacaThera独特的水凝胶平台技术，AmacaGel

™

, products developed by AmacaThera are designed to enhance the sustained delivery of therapeutic agents with a single injection, potentially revolutionizing animal care and welfare in veterinary medicine.

，AmacaThera 开发的产品旨在通过单次注射增强治疗剂的持续递送，这可能会彻底改变兽医学中的动物护理和福利。

Mike Cooke

迈克·库克

, Ph.D., CEO of AmacaThera, expressed his enthusiasm about the partnership: 'We are thrilled to be collaborating with Merck Animal Health, a global leader in animal health. Together, we see immense value in leveraging each other's expertise to explore new frontiers in animal health. This partnership reinforces our commitment to leverage our innovative technology to address important unmet needs in human and now veterinary medicine.'.

AmacaThera首席执行官（Ph.D.）对此次合作表示了极大的热情：“我们非常高兴能与动物健康领域的全球领导者默克动物健康合作。通过结合彼此的专业知识，我们看到了在动物健康领域探索新前沿的巨大价值。这一合作进一步巩固了我们利用创新技术解决人类以及现在兽医学中重要未满足需求的承诺。”

Chad Brown

查德·布朗

, Ph.D., Global Head, Pharmaceutical Sciences and Clinical Supply, and Associate Vice President of Merck Animal Health, added: 'We look forward to collaborating with AmacaThera as we continue to broaden our existing product portfolio of veterinary medicines and technology solutions. It is our hope to leverage our research knowledge and scientific expertise along with the hydrogel platform developed by AmacaThera, which may provide benefits for animal health and welfare.'.

博士，全球负责人，药物科学与临床供应，默克动物健康副总裁补充说：“我们期待与AmacaThera合作，继续扩大我们现有的兽药和技术解决方案产品组合。我们希望利用我们的研究知识和科学专长，结合AmacaThera开发的水凝胶平台，这可能为动物健康和福利带来益处。”

Cooke stated, 'This collaboration builds on our manufacturing know-how and in-human data collected from our hydrogel platform, enabling us to rapidly develop effective solutions for injectable delivery challenges.' He added, 'What sets our hydrogel apart is its broad compatibility with different drug modalities and that our manufacturing process is defined, fully saleable, and cost-effective.'.

库克表示：“这次合作建立在我们的制造知识和从我们的水凝胶平台收集的人体数据基础上，使我们能够快速开发出应对注射给药挑战的有效解决方案。”他补充道：“我们的水凝胶与众不同之处在于它与不同药物模式的广泛兼容性，并且我们的制造工艺是明确的、完全可扩展的且具有成本效益。”

Both companies anticipate a fruitful collaboration, with the shared goal of advancing innovative animal health solutions, thereby enabling veterinarians to provide better care.

两家公司都预计将迎来富有成效的合作，共同致力于推进创新的动物健康解决方案，从而让兽医能够提供更好的护理。

About AmacaThera

关于AmacaThera

AmacaThera is a clinical-stage biotechnology company focused on advanced sustained-release hydrogel formulations designed to address critical challenges in therapeutic drug delivery. The Company's flagship platform, AmacaGel™, enables the development of long-acting therapies that enhance patient outcomes while minimizing systemic side effects.

AmacaThera是一家临床阶段的生物技术公司，专注于先进的缓释水凝胶配方，旨在解决治疗性药物递送中的关键挑战。该公司的旗舰平台AmacaGel™能够开发长效疗法，在提升患者疗效的同时将全身副作用降至最低。

AmacaThera is driving innovation in key therapeutic areas, including pain management and oncology..

AmacaThera正在推动关键治疗领域的创新，包括疼痛管理和肿瘤学。

The Company's lead product, AMT-143, is currently advancing into Phase 2 clinical trials. It has demonstrated best-in-class pharmacokinetics, showing strong potential to as an alternative to opioid-based solutions in post-operative pain management.

公司的主要产品AMT-143目前正进入二期临床试验。它展现了同类最佳的药代动力学特性，在术后疼痛管理中显示出作为阿片类药物替代方案的强大潜力。

AmacaThera's proprietary AmacaGel™ platform is a fast-gelling physical hydrogel composed of two well-established polymers. Designed to liquefy under shear force, AmacaGel can be delivered via a conventional syringe and rapidly forms a depot as it warms to body temperature. The platform's lead asset, AMT-143, is a slow-release, non-opioid local anesthetic that leverages the AmacaGel™ technology to provide long-acting post-operative pain relief..

AmacaThera的专有AmacaGel™平台是一种由两种成熟聚合物组成的快速凝胶化的物理水凝胶。AmacaGel设计为在剪切力下液化，可以通过传统注射器递送，并在升温至体温时迅速形成储库。该平台的主要资产AMT-143是一种缓释、非阿片类局部麻醉剂，利用AmacaGel™技术提供长效的术后疼痛缓解。

For more information, consult our website

欲了解更多信息，请查阅我们的网站。

www.amacathera.com

About Merck Animal Health

关于默克动物保健

At Merck, known as MSD outside of

在默克，默克在美国和加拿大以外的地区被称为MSD

the United States

美国

and

和

Canada

加拿大

, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., .

，我们的目标是一致的：我们利用前沿科学的力量来拯救和改善世界各地的生命。一个多世纪以来，我们一直处于研究的前沿，为世界上最棘手的疾病带来药物、疫苗和创新的健康解决方案。默克动物健康公司是默克公司的一个部门。

Rahway, N.J.

Rahway，新泽西州

, USA, is the global animal health business of Merck. Through its commitment to The

美国是默克公司的全球动物健康业务部门。通过其对 The 的承诺

Science of Healthier Animals

动物更健康的科学

，

Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products.

默克动物保健公司为兽医、农民、生产商、宠物主人及政府提供范围最广的兽医药品、疫苗和健康管理解决方案及服务之一，同时还提供一套广泛的连接技术，包括识别、追溯和监测产品。

Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

默克动物保健致力于保护和改善动物及其照料者的健康、福祉和表现。公司大力投资于动态且全面的研发资源以及现代化的全球供应链。默克动物保健业务遍及50多个国家，产品在约150个市场有售。

For more information, visit .

欲了解更多信息，请访问。

www.merck-animal-health.com

and connect with us on

并关注我们

领英

，

Facebook

脸书

，

X (formerly Twitter)